Insomnia Therapeutics Market Size, Share, Trends, Growth Outlook

Insomnia Therapeutics Market is estimated to increase at a growth rate of 5.9% CAGR over the forecast period from 2024 to 2030.

The Insomnia Therapeutics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin antagonists, Melatonin antagonists, Others), Devices), By Sales Channel (Prescription, Over-the-Counter (OTC).

An Introduction to Insomnia Therapeutics Market in 2024

The Insomnia Therapeutics market in 2024 reflects a growing awareness of sleep disorders and their profound impact on overall health and well-being. With insomnia emerging as a prevalent condition affecting millions worldwide, pharmaceutical companies are striving to innovate novel pharmacological agents targeting diverse pathways involved in sleep regulation. Non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists constitute the cornerstone of pharmacotherapy for insomnia, offering improved sleep onset, maintenance, and quality without significant residual effects. Additionally, the market is witnessing a surge in demand for non-pharmacological interventions, including cognitive-behavioral therapy for insomnia (CBT-I), sleep hygiene education, and relaxation techniques, reflecting a holistic approach towards managing sleep disturbances and promoting healthy sleep habits.

Insomnia Therapeutics Market Trend: Rising Demand for Non-Pharmacological Interventions

A significant trend in the Insomnia Therapeutics market is the increasing demand for non-pharmacological interventions to manage insomnia. As concerns about the long-term use and potential side effects of prescription sleep medications grow, patients are seeking alternative approaches to improve sleep quality and duration. Non-pharmacological treatments such as cognitive behavioral therapy for insomnia (CBT-I), relaxation techniques, sleep hygiene education, and lifestyle modifications are gaining popularity as effective and sustainable options for addressing insomnia symptoms. This trend reflects a broader shift towards holistic and personalized approaches to sleep management, emphasizing behavioral and lifestyle interventions alongside or instead of pharmacotherapy.

Market Driver: Growing Awareness of Insomnia's Impact on Health and Well-being

A key driver propelling the Insomnia Therapeutics market is the growing awareness of insomnia's profound impact on health and well-being. Increasing recognition of insomnia as a serious medical condition associated with numerous adverse health outcomes, including impaired cognitive function, mood disturbances, cardiovascular disease, obesity, and decreased quality of life, is driving individuals to seek treatment for their sleep difficulties. Healthcare providers are also becoming more proactive in identifying and addressing insomnia in their patients, leading to greater diagnosis rates and treatment-seeking behavior. This heightened awareness and understanding of the consequences of untreated insomnia are driving the demand for effective therapeutic interventions.

Insomnia Therapeutics Market Opportunity: Development of Novel Pharmacological Treatments with Improved Safety and Efficacy Profiles

An opportunity in the Insomnia Therapeutics market lies in the development of novel pharmacological treatments with improved safety and efficacy profiles. While existing pharmacotherapy options such as benzodiazepines, non-benzodiazepine hypnotics, and sedating antidepressants are commonly prescribed for insomnia, they are associated with limitations such as dependency, tolerance, rebound insomnia, and adverse effects. There is a need for innovative medications that target novel pathways involved in sleep regulation while minimizing side effects and risks of long-term use. Investing in research and development efforts to discover and develop new insomnia medications with enhanced efficacy, safety, and tolerability profiles presents an opportunity for pharmaceutical companies to address unmet patient needs and capture market share in the rapidly evolving insomnia therapeutics landscape.

Insomnia Therapeutics Market Segmentation

By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Insomnia Therapeutics Market Companies

Abbott Laboratories
Aurobindo Pharma Ltd
Eisai Co. Ltd
Electromedical Products International Inc
Idorsia Pharmaceuticals Ltd
INNOVATIVE NEUROLOGICAL DEVICES LLC
Mallinckrodt Plc
MEDICE Arzneimittel Putter GmbH and Co. KG
Merck and Co. Inc
Minerva Neurosciences Inc
Neurim Pharmaceuticals Ltd
Pfizer Inc
Questex LLC
Sanofi
Sumitomo Pharma Co. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co. Ltd
Vanda Pharmaceuticals Inc
Viatris Inc

 

 

Reasons to Buy the Insomnia Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Insomnia Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Insomnia Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Insomnia Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Insomnia Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Insomnia Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Insomnia Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Insomnia Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Insomnia Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Insomnia Therapeutics Market Industry
4.2 Key Market Trends in Insomnia Therapeutics Market Industry
4.3 Potential Opportunities in Insomnia Therapeutics Market Industry
4.4 Key Challenges in Insomnia Therapeutics Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Insomnia Therapeutics Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Insomnia Therapeutics Market Outlook By Segments
7.1 Insomnia Therapeutics Market Outlook by Segments
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

8 North America Insomnia Therapeutics Market Analysis And Outlook To 2030
8.1 Introduction to North America Insomnia Therapeutics Markets in 2024
8.2 North America Insomnia Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Insomnia Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

9 Europe Insomnia Therapeutics Market Analysis And Outlook To 2030
9.1 Introduction to Europe Insomnia Therapeutics Markets in 2024
9.2 Europe Insomnia Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Insomnia Therapeutics Market Size Outlook By Segments, 2021-2030
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

10 Asia Pacific Insomnia Therapeutics Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Insomnia Therapeutics Markets in 2024
10.2 Asia Pacific Insomnia Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Insomnia Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

11 South America Insomnia Therapeutics Market Analysis And Outlook To 2030
11.1 Introduction to South America Insomnia Therapeutics Markets in 2024
11.2 South America Insomnia Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Insomnia Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

12 Middle East And Africa Insomnia Therapeutics Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Insomnia Therapeutics Markets in 2024
12.2 Middle East and Africa Insomnia Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Insomnia Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Aurobindo Pharma Ltd
Eisai Co. Ltd
Electromedical Products International Inc
Idorsia Pharmaceuticals Ltd
INNOVATIVE NEUROLOGICAL DEVICES LLC
Mallinckrodt Plc
MEDICE Arzneimittel Putter GmbH and Co. KG
Merck and Co. Inc
Minerva Neurosciences Inc
Neurim Pharmaceuticals Ltd
Pfizer Inc
Questex LLC
Sanofi
Sumitomo Pharma Co. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co. Ltd
Vanda Pharmaceuticals Inc
Viatris Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Drugs
-Benzodiazepines
-Nonbenzodiazepines
-Antidepressants
-Orexin antagonists
-Melatonin antagonists
-Others
Devices
By Sales Channel
Prescription
Over-the-Counter (OTC)